Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its $35.2 million initial public offering AstraZeneca acquired Caelum Biosciences; Fortress received $56.9 million upfront1 Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to be initiated in the fourth quarter of 2021 Top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma expected around year-end 2021